Abstract: Stable, constitutively expressed, chromosomal fluorescent transcriptional fusions in bacterial pathogens and methods of using the same to screen candidate compounds for anti-bacterial efficacy.

Abstract: A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include assays for total bacterial growth, bacterial metabolic activity, and biofilm formation. The series of assays may be run once or more than once at each tier. A library of compounds is subject to tier A and only compounds meeting a primary parameter advance to tier B, and only tier B compounds meeting a confirmation parameter advance to tier C, and only tier C compounds meeting a dose-response parameter are identified as putative agents effective for inhibiting and/or eradicating a biofilm, further wherein the assays are conducted for each compound subject to the respective tier.

Abstract: A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include assays for total bacterial growth, bacterial metabolic activity, and biofilm formation. The series of assays may be run once or more than once at each tier. A library of compounds is subject to tier A and only compounds meeting a primary parameter advance to tier B, and only tier B compounds meeting a confirmation parameter advance to tier C, and only tier C compounds meeting a dose-response parameter are identified as putative agents effective for inhibiting and/or eradicating a biofilm, further wherein the assays are conducted for each compound subject to the respective tier.

Abstract: A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include as says for total bacterial growth, bacterial metabolic activity, and biofilm formation.

Abstract: Compositions and methods of utilizing the same are provided for treating bacterial infections. The compositions comprise acidified nitrite in combination with an iron chelator and an antibiotic. The compositions of the present invention are effective at treating bacterial infections with minimal to no side effects. Surprisingly, the combination of these three agents has a synergistic effect, which advantageously permits a lower dose of one or more of the active agents (e.g., the antibiotic).

Abstract: Compositions and methods of utilizing the same are provided for treating bacterial infections. The compositions comprise acidified nitrite in combination with an iron chelator and an antibiotic. The compositions of the present invention are effective at treating bacterial infections with minimal to no side effects. Surprisingly, the combination of these three agents has a synergistic effect, which advantageously permits a lower dose of one or more of the active agents (e.g., the antibiotic).

Abstract: A high through-put screening method for identifying agents effective for inhibiting biofilm formation and/or killing established biofilm are disclosed. The method includes three tiers, and each tier includes three specific biological process assays. The tier levels are a primary screen, a confirmation screen, and a dose-response screen, and the biological process assays include as says for total bacterial growth, bacterial metabolic activity, and biofilm formation.

Abstract: Provided herein are compositions, methods and systems to prevent unauthorized use or release into the environment of genetically modified organisms or cells which comprises a) a genetically modified organism or cell and b) one or more keys, wherein contacting the genetically modified organisms or cell with the key results in viability or unviability of the genetically modified organism or cell.

Abstract: Stable, constitutively expressed, chromosomal fluorescent transcriptional fusions in bacterial pathogens and methods of using the same to screen candidate compounds for anti-bacterial efficacy.

Abstract: Methods for treating bacterial respiratory tract infections in an individual comprise administering a therapeutic amount of nitrite composition having a pH of less than 7, and in specific embodiments, a pH of about 5.5-6.5, to the individual. The individual may be a pulmonary disease diagnosed individual and/or the infection may be at least in part caused by mucoid mucA mutant Pseudomonas aeruginosa.

Abstract: Transgenic microbes with an altered electrogenic efficacy, biofilms comprising such microbes, and microbial fuel cells comprising such microbes are provided. The microbial fuel cells can be operated as monitors, filtration devices, and sensors.

Abstract: Transgenic microbes with an altered electrogenic efficacy, biofilms comprising such microbes, and microbial fuel cells comprising such microbes are provided. The microbial fuel cells can be operated as monitors, filtration devices, and sensors.

Abstract: Microbial fuel cells may include anode(s), cathode(s) and a biofilm attached to at least the anode. The biofilm may include bacterial cells adapted to facilitate transfer of a plurality of electrons to the anode from a feedstock. In an example embodiment, a microbial fuel surface may include a large surface area to volume ratio in order to increase power (electron) generation and/or transfer.

Abstract: Methods for treating bacterial respiratory tract infections in an individual comprise administering a therapeutic amount of nitrite composition having a pH of less than 7, and in specific embodiments, a pH of about 5.5-6.5, to the individual. The individual may be a pulmonary disease diagnosed individual and/or the infection may be at least in part caused by mucoid mucA mutant Pseudomonas aeruginosa.

Abstract: Methods for Cystic Fibrosis disease assessment in an individual comprise detecting the presence or absence of outer membrane protein in a sample from an individual or the methods comprise detecting the presence or absence of outer membrane protein antibodies in a sample from an individual. Methods for treating anaerobic Pseudomonas aeruginosa biofilms in Cystic Fibrosis disease comprise detecting the presence of outer membrane protein in a sample from an individual; and selecting a therapy regimen for the individual based on the presence of OprF, wherein the anaerobic Pseudomonas aeruginosa biofilms in Cystic Fibrosis disease are treated by the therapy regimen or the methods comprise detecting the presence of outer membrane protein antibodies in a sample from an individual; and selecting a therapy regimen for the individual based on the presence of OprF antibodies; wherein the anaerobic Pseudomonas aeruginosa biofilms in Cystic Fibrosis disease are treated by the therapy regimen.